CN103990118B - A kind for the treatment of injects the combination medicament that somatomedin causes hypertrophy - Google Patents
A kind for the treatment of injects the combination medicament that somatomedin causes hypertrophy Download PDFInfo
- Publication number
- CN103990118B CN103990118B CN201410252997.XA CN201410252997A CN103990118B CN 103990118 B CN103990118 B CN 103990118B CN 201410252997 A CN201410252997 A CN 201410252997A CN 103990118 B CN103990118 B CN 103990118B
- Authority
- CN
- China
- Prior art keywords
- injection
- combination medicament
- treatment
- parts
- hypertrophy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides a kind of injection somatomedin for the treatment of and cause the combination medicament of hypertrophy, this combination medicament comprises the composition of following mass ratio: the injection recombinant human interferon alpha 2 of the FUFANG DANSHEN ZHUSHEYE of 100 parts ~ 400 parts, the glucocorticoid injection of 0.1 part ~ 50 parts, the Fluorouracil Injection of 0.1 part ~ 1 part, the injection hyaluronidase of 0.5 part ~ 300 parts and 1 part ~ 10 parts.The invention has the beneficial effects as follows: a kind for the treatment of provided by the invention injects the combination medicament that somatomedin causes hypertrophy, onset speed is fast, and cure rate is high, and toxic and side effects is little, relapse rate is extremely low, effectively can treat all types of soft tissue hyperplasia that subcutaneous injection fibroblast growth factor causes.
Description
Technical field
The present invention relates to the technical field of medical drug, refer more particularly to a kind for the treatment of and inject the combination medicament that somatomedin causes hypertrophy.
Background technology
At present, due to beauty and shaping market confusion, illegal medical institutions and itinerant doctor, when determining injection product safety, to plastic patients face, cervical region and chest illegally inject some biological product containing fibroblast growth factor and so on, cause the abnormal differentiation of a large amount of patient's injection areas soft tissue cells therefrom, cause a large amount of granuloma case hypertrophy, if controlled not in time, have the trend of malignant development.
Be super category illegal use and the special case formed owing to being injected into fibroblast growth factor, so be directed to the problem that subcutaneous injection fibroblast growth factor causes hyperplasia, various big hospital did not do correlational study targetedly, tentative treatment can only be carried out according to a conventional method, and have no idea to ensure any postoperative effect, the more conventional therapeutic scheme of present hospital have following some:
Subcutaneous injection triamcinolone acetonide, get Bao Song, the glucocorticoid medicine of prednisolone and so on, or conbined usage antitumor drug synchronous therapeutic.
But, because the side effect of glucocorticoid and antitumor drug is large, and a lot of irreversible negative effect is caused to patient, as: pigmentation, excessive depression, the red blood streak phenomenon that telangiectasis is formed, the skin albinism that blood capillary atrophy is formed, endocrine disturbance, moon face etc.Its main problem is that treated effect entirety is not high, general easily recurrence, and often, the PATIENT POPULATION that the multiple side effect of medicine body causes does not tolerate in treatment, and therapy discontinued.
Routine operation Resection in Treatment, comparatively speaking, postoperative instantaneity effectiveness comparison is good, but skin of face is organized thinner, and tension force is large; The situation that after excision, operative region subsides often has generation, and in recovering after surgery, in the sub-dermal soft tissue wound healing process that operation is formed, is subject to skin high tension, enriches the reason of blood fortune, can form new sub-dermal soft tissue scar hyperplasia.
Erbium doped fiber laser therapeutic instrument, by diameter 2mm small optical fiber, plasma light is directly accurately transmitted to subcutaneous (skin corium) or SMAS fascia layer, at hypertrophy region abrupt release photo-thermal energy, by hyperplastic tissue's Quick-gasifying and liquefaction, the gasification formed, liquefied material is fallen by the soft tissue blood in later stage and body fluid metabolic.But one of major function demand of Erbium doped fiber laser therapeutic instrument own is that subcutaneous intervention promotes that skin collagen is formed.That new problem has occurred, the patient doing the transconversion into heat of hyper-proliferative body optical fiber appearance area for treatment swelling in various degree after surgery, the problem that skin histology thickens.The subcutaneous fat of patient also indirectly gasifies and liquefies by another side effect, because the fusing point of fat is all lower than its hetero-organization of surrounding, so when optical fiber topical therapeutic, fat is lost faster than other soft tissues, postoperatively just forms rough situation at skin surface.
Summary of the invention
The object of the invention is to overcome the deficiencies in the prior art, providing a kind for the treatment of and injecting the combination medicament that somatomedin causes hypertrophy.
The present invention is realized by above technical scheme: the invention provides a kind of injection somatomedin for the treatment of and cause the combination medicament of hypertrophy, this combination medicament comprises the composition of following mass ratio: the injection recombinant human interferon alpha 2 of the FUFANG DANSHEN ZHUSHEYE of 100 parts ~ 400 parts, the glucocorticoid injection of 0.1 part ~ 50 parts, the Fluorouracil Injection of 0.1 part ~ 1 part, the injection hyaluronidase of 0.5 part ~ 300 parts and 1 part ~ 10 parts.
Preferably, the concrete dosage of described FUFANG DANSHEN ZHUSHEYE is 200 parts.
Preferably, described glucocorticoid is specially: cortisone, hydrocortisone, meticortelone, prednisolone, Methyllprednisolone, 6.alpha.-fluoro-16.alpha.-methylprednisolone, fluprednisolone, triamcinolone, betamethasone, dexamethasone or beclomethasone.
Preferably, the concrete composition of described glucocorticoid is: 20 parts.
Preferably, injection collagenase is: 1 type injection collagenase, 2 type injection collagenases, 3 type injection collagenases or 4 type injection collagenases.
The invention has the beneficial effects as follows: a kind for the treatment of provided by the invention injects the combination medicament that somatomedin causes hypertrophy, onset speed is fast, and cure rate is high, and toxic and side effects is little, relapse rate is extremely low, effectively can treat all types of soft tissue hyperplasia that subcutaneous injection fibroblast growth factor causes.
Detailed description of the invention
In order to make object of the present invention, technical scheme and advantage clearly understand, the present invention is further elaborated in conjunction with the embodiments.Should be appreciated that specific embodiment described herein only in order to explain the present invention, be not intended to limit the present invention.
Embodiments provide a kind of injection somatomedin for the treatment of and cause the combination medicament of hypertrophy, this combination medicament comprises the composition of following mass ratio: the injection recombinant human interferon alpha 2 of the FUFANG DANSHEN ZHUSHEYE of 100 parts ~ 400 parts, the glucocorticoid injection of 0.1 part ~ 50 parts, the Fluorouracil Injection of 0.1 part ~ 1 part, the injection hyaluronidase of 0.5 part ~ 300 parts and 1 part ~ 10 parts.
The concrete dosage of concrete described FUFANG DANSHEN ZHUSHEYE is 200 parts, FUFANG DANSHEN ZHUSHEYE has Radix Notoginseng and Radix Salviae Miltiorrhizae preparation, a large amount of clinical verification, FUFANG DANSHEN ZHUSHEYE not only can blood circulation promoting and blood stasis dispelling, accelerate microcirculation metabolism, and effectively can suppress the fibroblastic propagation in soft tissue hyperplasia body, the synthesis of collagen stroma can be reduced, reduce collagen deposition, accelerate the apoptosis atrophy of hyperplastic tissue.
Glucocorticoid is wherein specially: cortisone, hydrocortisone, meticortelone, prednisolone, Methyllprednisolone, 6.alpha.-fluoro-16.alpha.-methylprednisolone, fluprednisolone, triamcinolone, betamethasone, dexamethasone or beclomethasone.Glucocorticoid medicine has stronger antiinflammatory anti-allergy action, and at the inflammation initial stage, GCS suppresses telangiectasis, alleviates and oozes out and edema, suppresses again the infiltration of leukocyte and engulfs, and the symptom that reduces inflammation.In the inflammation later stage, suppress the hypertrophy of blood capillary and fibroblast, delay the generation of granulation tissue.And alleviate the inflammatory sequelae such as cicatrix and adhesion.Divide short according to its plasma half-life, in, long-acting three classes.Plasma half-life refers to the time of the plasma concentration drop by half of medicine, and its length has nothing to do with plasma concentration as a rule, its reflection medicine excretion in vivo, the biological speed transforming and store.Biological half-life refers to the time of medicine drop by half.Generally plasma half-life and biological half-life correlation.Fugitive hormone comprises: hydrocortisone, cortisone, and middle effect hormone comprises: prednisone, meticortelone, methyl meticortelone, omcilon.Long-acting hormone comprises: dexamethasone, the medicines such as betamethasone.Dose,equivalent is scaled: cortisone 25=hydrocortisone 20=prednisone 5=meticortelone 5=prednisolone 4=Methyllprednisolone 4=6.alpha.-fluoro-16.alpha.-methylprednisolone 2=fluprednisolone 1.5=triamcinolone 4=betamethasone 8=dexamethasone 75=beclomethasone 5, according to soft patient tissues's accretion prism state concrete condition, the different types of glucocorticoid of choice for use, preferably, effective dose is 20 parts.
Fluorouracil Injection is wherein a kind of immunosuppressant of antimetabolic, makes DNA and RNA biosynthesis block, thus is suppressed to fibrocellular growing multiplication.
Injection hyaluronidase wherein, for protease, Hyaluronic Acid mucopolysaccharide in energy break-up tissue substrate, make the amidohexose bond fission between the C1 of glucosamine and the C4 of glucuronic acid, mucopolysaccharide degraded in tissue, content reduces, and local organization flattens, deliquescing, makes the transudate of the medicinal liquid of injection and pathological changes local be easy to diffusion and absorb.
Injection collagenase wherein belongs to metalloproteases (MP), has the ability of specific for hydrolysis collagen fiber three helical region peptide chain structure, and collagen fiber, only after triple-helix structure is damaged, just can be degraded.Concrete, injection collagenase is: 1 type injection collagenase, 2 type injection collagenases, 3 type injection collagenases or 4 type injection collagenases.
Injection recombinant human interferon alpha 2 wherein: interferon is the glycoprotein that antigen or mitogen etc. stimulate the generation of Th1 cell, be called interferon type Ⅱ or immune interferon, there is T suppression cell increment, Cell differentiation inducing activity, strengthen the effect such as natural killer cell and macrophage activity, play antiviral, antitumor and immunoloregulation function.
The present invention is described in further detail below: the present embodiment is implemented under premised on technical solution of the present invention, gives detailed embodiment, but protection scope of the present invention is not limited to following embodiment:
This treatment subcutaneous injection basic fibroblast growth factor causes the pharmaceutical agent combinations of soft tissue hyperplasia, and treatment subcutaneous injection contains the composite growth factor of fibroblast growth factor, and PRP or growth peptide cause the pharmaceutical agent combinations of soft tissue hyperplasia.
Medicament each component proportion method is as follows: injection recombinant human interferon alpha 2 1,000,000 unit (), injection hyaluronidase 1500 unit (one) and injection collagenase 1200 unit () first use 2% lidocaine injection (solvent is used) 2ml to dissolve completely respectively, FUFANG DANSHEN ZHUSHEYE 1----4ml is drawn respectively again with 10ml disposable syringe, glucocorticoid injection 1mg-500mg, Fluorouracil Injection 1-10ml, complete mixing for standby use.
Treatment is implemented: because subcutaneous injection somatomedin causes patient 163 example of hyperplasia, soft patient tissues's hypertrophy type: Tuberculous hypertrophy 36 example, hypertrophica hypertrophy 102 example, fatty hypertrophy 25 example.After skin routine disinfection, under accretion prism central area, pin is in radiation injection or around accretion prism center multi-point injection, spacing 1 centimetre, every pin mark administration 1-2ml, be injected to feeling of repletion, epidermis turns white slightly, depth of needling can not be crossed dark or show shallow, based on accretion prism central core.Injection in every 3 weeks once, is for three times a course for the treatment of.
Curative effect determinate standard: recovery from illness: accretion prism 100% atrophy is degraded, skin-color state is normal, and quality is put down soft, without protuberance, without any sense of discomfort.Effective: accretion prism 80% atrophy is degraded, skin-color state is normal, and quality is put down soft, without protuberance, accidentally has sense of discomfort.Take a turn for the better: accretion prism 50% atrophy is degraded, and skin-color state is normal, and quality is put down soft, swells not obvious, occasionally have sense of discomfort, treat still effective.Invalid: through 3 injection for curing course for the treatment of, all symptoms have no improvement.
Therapeutic outcome: recovery from illness 105 example, effective: 35 examples, take a turn for the better 19 examples, and invalid 4 examples, total effective rate is 97%.
Can be found out by foregoing description, the treatment injection somatomedin that the present embodiment provides causes the combination medicament onset speed of hypertrophy fast, and cure rate is high, and toxic and side effects is little, relapse rate is extremely low, effectively can treat all types of soft tissue hyperplasia that subcutaneous injection fibroblast growth factor causes.
These are only preferred embodiment of the present invention, not in order to limit the present invention, all any amendments done within the spirit and principles in the present invention, equivalent replacement and improvement etc., all should be included within protection scope of the present invention.
Claims (3)
1. treat the combination medicament that injection somatomedin causes hypertrophy for one kind, it is characterized in that, this combination medicament comprises the composition of following mass ratio: injection recombinant human interferon alpha 2 1,000,000 unit, injection hyaluronidase 1500 unit and injection collagenase 1200 unit, 2% lidocaine injection 2ml, FUFANG DANSHEN ZHUSHEYE 1-4ml, the glucocorticoid injection of 1mg-500mg, the Fluorouracil Injection of 1-10ml.
2. treatment injection somatomedin according to claim 1 causes the combination medicament of hypertrophy, it is characterized in that, described glucocorticoid is specially: cortisone, hydrocortisone, meticortelone, prednisolone, Methyllprednisolone, 6.alpha.-fluoro-16.alpha.-methylprednisolone, fluprednisolone, triamcinolone, betamethasone, dexamethasone or beclomethasone.
3. treatment injection somatomedin according to claim 1 causes the combination medicament of hypertrophy, and it is characterized in that, described injection collagenase is: 1 type injection collagenase, 2 type injection collagenases, 3 type injection collagenases or 4 type injection collagenases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410252997.XA CN103990118B (en) | 2014-06-10 | 2014-06-10 | A kind for the treatment of injects the combination medicament that somatomedin causes hypertrophy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410252997.XA CN103990118B (en) | 2014-06-10 | 2014-06-10 | A kind for the treatment of injects the combination medicament that somatomedin causes hypertrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103990118A CN103990118A (en) | 2014-08-20 |
| CN103990118B true CN103990118B (en) | 2016-03-02 |
Family
ID=51304615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410252997.XA Active CN103990118B (en) | 2014-06-10 | 2014-06-10 | A kind for the treatment of injects the combination medicament that somatomedin causes hypertrophy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103990118B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115350199A (en) * | 2022-08-03 | 2022-11-18 | 新时代针功夫(福州台江区)门诊部有限公司 | Formula for dissolving scar tissue of growth factor hyperplasia and inhibiting growth |
-
2014
- 2014-06-10 CN CN201410252997.XA patent/CN103990118B/en active Active
Non-Patent Citations (3)
| Title |
|---|
| 增生性疤痕及疤痕疙瘩的非手术治疗;王量等;《中国美容整形外科杂志》;20120730;第23卷(第7期);第438页 * |
| 川穹嗪等中药针剂对兔耳增生性瘢痕作用的实验研究;苏毅鹏;《中国优秀硕士论文全文数据库，医药卫生科技辑》;20030315(第01期);中文摘要部分 * |
| 瘢痕的非手术治疗 网址：www.zhengxing.com.cn/ArticleShow.aspx?ArticleID=1585;蔡景龙等;《中国医学科学院整形外科医院（整形外科研究所）》;20091214;第四部分：瘢痕内药物注射治疗部分 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103990118A (en) | 2014-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102284051B (en) | Medicine for treating chloasma | |
| CN1154856A (en) | Natural freckle-diminishing face-beautifying product and peparation method thereof | |
| CN102120001B (en) | Jiuhua hemorrhoid suppository and preparation method thereof | |
| Shen et al. | Research progress of scar repair and its influence on physical and mental health | |
| CN102908394A (en) | Chinese medicament for activating promoting blood circulation to remove blood stasis and relieving pains | |
| CN103990118B (en) | A kind for the treatment of injects the combination medicament that somatomedin causes hypertrophy | |
| CN102198091B (en) | Acupuncture point injection | |
| CN101167821A (en) | External-applied traditional Chinese medicine for curing breast cancer and its preparation method | |
| CN103263470B (en) | Swelling-decreasing and pain-relieving traditional Chinese medicine gel and preparation method thereof | |
| CN109303811A (en) | The exterior-applied medical wine of activating microcirculation and removing stasis medicinal anti-inflammatory analgetic | |
| CN103393918B (en) | Compounded garcinia and radix angelicae ointment for preventing and treating chemotherapeutic phlebitis | |
| CN105434545A (en) | Preparation and application of drug percutaneous absorbent | |
| CN102579458A (en) | Medicament formula for relieving pain caused by infusion medicament and preventing phlebitis | |
| CN100998604B (en) | Traditional Chinese medicine for treat burns and scald and its preparing method | |
| Chen et al. | Microneedling in the relief of pain in arthritis: a brief review | |
| Laser Cosmetology Group, Medical Aesthetics and Cosmetology Branch of Chinese Medical Association et al. | Consensus on treatment of acne scars in China (2021) | |
| CN104274584B (en) | A kind of preparation method of hair growth Tibetan medicine | |
| CN1981865A (en) | Formula and usage for treating acne | |
| RU2286791C1 (en) | Method for cicatrice treatment | |
| RU2811255C1 (en) | Method of treating rosacea conglobate by points | |
| CN114099629B (en) | Percutaneous administration preparation for treating breast nodules and preparation method thereof | |
| CN102670754A (en) | Traditional Chinese medicine composition for treating mammary gland hyperplasia and preparation process thereof | |
| CN101574504B (en) | Medical composition for treating mammary gland diseases and preparation method thereof | |
| Gentile et al. | Treatment of insulin-induced skin lipohypertrophy: Costs and sustainability of liposuction and education | |
| CN105878427A (en) | Peony seed oil compound spray for curing burn and scald and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |